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Abstract
Noroviruses are associated with intestinal disease in humans, cows, pigs, mice, and, more recently, dogs. In 2007, the first
canine norovirus (CNV) was identified and characterized in Italy. Subsequent studies have identified CNV in stools of dogs
from Portugal, Greece, and the United States. To investigate the prevalence of CNV in the UK dog population, 228 canine
stool samples were screened for CNV by qPCR, and 396 serum samples were screened for anti-CNV antibodies. qPCR of RNA
extracted from canine stool samples did not reveal any CNV-positive samples, based on samples collected from diarrhoeic
and control dogs in 2012–2013. CNV virus-like particles to three different CNV strains were produced using recombinant
baculoviruses and a seroprevalence screen undertaken. Anti-CNV antibodies were identified at significant levels in canine
serum; 38.1% of samples collected between 1999–2001 and 60.1% of samples collected in 2012–2013 were seropositive.
The increase in seroprevalence over time (p,0.001) suggests that the CNV strains screened for are becoming more
widespread. Variation in seroprevalence to different CNV strains was also identified. Two-thirds of the dogs were
seropositive to a single strain, whereas the remaining third were seropositive to two or three of the strains analysed. This
study has provided the first evidence that CNV is present in the UK, with seroprevalence identified to multiple circulating
strains. This warrants further study and increased awareness of this recently discovered canine virus.
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Introduction
Noroviruses are members of the RNA virus family Caliciviridae,
and are a major cause of human infectious gastroenteritis
worldwide. An estimated three million people each year in the
UK suffer from ‘winter vomiting disease’ caused by human
norovirus [1]. Infection causes the classic symptoms of vomiting,
diarrhea and malaise, and outbreaks are common in closed or
semi-closed communities such as in hospitals, care homes, schools
and cruise ships. In addition to the major burden of noroviruses on
human health, noroviruses have also been found associated with
intestinal disease in cows [2], pigs [3], mice [4], a lion [5], cats [6]
and dogs [7]. The first canine norovirus (CNV) was reported from
a single dog with enteritis in Italy in 2007. Subsequent studies have
identified CNV in stools of dogs from Portugal [8,9], Greece [10]
and the US [11]. To date there have been no reports of CNV
present in the UK.
Significant sequence variation has been found in different CNV
strains identified to date. Noroviruses are assigned to six
genogroups based on complete capsid sequences, with strains of
norovirus assigned to the same genogroup if they share 55–85%
amino acid identity [12]. Human noroviruses are grouped
together in genogroups I, II and IV whereas CNV strains have
been assigned to genogroups IV and VI. Human and canine
noroviruses in genogroup IV share ,85% amino acid identity,
thus are separated into different genotypes, IV.1 and IV.2
respectively. Genetic recombination is believed to occur between
different norovirus strains, which may explain the significant
heterogeneity between the CNV strains identified [13].
The prevalence of CNV in dogs with clinical signs of
gastroenteritis across Europe has been estimated to be between
2.1% (Italy [13]) and 40% (Portugal [8]). A study in the US
identified CNV at a prevalence of 11% in canine diarrhoea
samples [11]. CNV has also been detected in healthy dogs [8], and
the association between infection and clinical signs is yet to be
formally established. CNV has been identified in dogs also infected
with other enteric viral pathogens such as canine parvovirus (CPV)
and canine enteric coronavirus (CECoV), thus elucidating the role
of CNV infection in disease is difficult.
Serological prevalence of CNV in countries where the virus has
been detected has not been reported. A preliminary serological
survey in Italy suggested less than 5% dogs were seropositive to a
genogroup IV.2 lion norovirus (strain Pistoia/387/06/ITA) but
the sample size was small [14]. As with human norovirus, CNV
has yet to be cultivated in cell culture thus obtaining sufficient
quantities of virus for serological screening is not possible.
However, the major capsid protein of noroviruses (VP1) has been
shown to spontaneously assemble into virus-like particles (VLPs)
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when recombinant VP1 is expressed in an appropriate system
[15]. Production of lion and canine norovirus VLPs has previously
been achieved and proven to be an efficient way of generating
antigen for serological analysis [14,16].
The aim of this study was to elucidate the importance of CNV
in the UK dog population and evaluate any changes over time. No
prior information on CNV prevalence in the UK has been
described, so in order to address this our study has sought to
determine the prevalence of CNV RNA in canine fecal samples, in
conjunction with the prevalence of anti-CNV antibodies in
different populations of dogs.
Methods
Ethics Statement
No ethical approval was required for this study as all clinical
samples collected were either animal waste products, surplus to
diagnostic requirements, or derived from a previously published
and ethically approved study [17].
Samples
Stool samples were collected from dogs admitted to four
participating veterinary clinics in geographically distinct areas
across the UK. With owner consent, dogs were recruited to the
study if they passed stools whilst hospitalized. Stools were collected
by veterinary personnel, then stored at 220uC until and during
transportation to the laboratory, whereafter they were stored at
280uC prior to nucleic acid extraction. Stool samples were also
collected from healthy dogs owned by veterinary staff at each
clinic, as well as from dogs at participating boarding kennels. Basic
case data was recorded for each dog from which a stool sample
was collected, including age, breed, sex, reason for admission, and
any recent history of enteric disease.
Serum samples were obtained from two separate dog popula-
tions. Samples from 1999–2001 were collected from a rehoming
kennel as part of an existing study [17]. Serum samples from
2012–2013 were obtained from the diagnostic service of the Royal
Veterinary College, and from the UK Pet Blood Bank. These sera
were collected from pet dogs that were either blood donors, or
veterinary patients from which blood was collected for biochem-
ical analysis for various reasons.
Nucleic Acid Extraction and qRT-PCR
Stools were diluted 10% w/v in phosphate-buffered saline,
pH 7.2, and solids were removed by centrifugation at 80006g for
5 min. Viral nucleic acid was extracted from 140 ml of each
clarified stool suspension by the GenEluteTM Mammalian Total
RNA Miniprep Kit (Sigma Aldrich) according to the manufac-
turers’ instructions.
An internal extraction control was added to each sample during
nucleic acid extraction to verify removal of PCR inhibitors and
enable precise quantification of viral nucleic acid. A fixed amount
of Equine Arteritis Virus (EAV) RNA was added with the lysis
buffer to each sample to obtain an EAV concentration of
approximately 16108 copies per ml of faecal suspension.
qRT-PCR was selected as the screening method as its high
sensitivity allows for the detection of lower viral copy numbers
than conventional PCR. All 6 CNV sequences listed in Genbank
in August 2012 (table 1) were used to design a CNV specific
primer-probe (PrimerDesign Ltd, table 2). The target sequence is
the highly conserved region of the RdRp (NS7). A positive control
amplicon was used to generate a standard curve. As few as 100
copies of the CNV amplicon were reliably detected in a reaction
volume of 20 ml. In addition to CNV, samples were also screened
for two other canine enteric viruses known to be circulating in the
UK. Primer-probes used for canine parvovirus (CPV) and canine
enteric coronavirus (CECoV) are listed in table 2, as well as the
primer-probe sequence used to detect the internal extraction
control.
A 1-step qRT-PCR protocol was used to improve ease and
efficiency of sample handling. 2 ml of extracted RNA was added to
26Precision OneStep qRT-PCR MasterMix (PrimerDesign Ltd),
6 pMol/ml primers, and 3 pMol/ml probe. The thermal cycle
protocol used with a ViiA7 qPCR machine (AB Applied
Biosystems), was as follows: 55uC for 30 mins, inactivation of
reverse transcriptase at 95uC for 5 mins, and then 40 cycles
consisting of denaturation at 95uC for 15 s, then annealing and
elongation at 60uC for 1 min.
Virus-like Particle (VLP) Production
Three different CNV strains with maximum sequence differ-
ence were selected for VLP production. The sequences of the three
CNV-VP1 genes were obtained from GenBank (table 1) and
restriction enzymes sites designed (59 NotI for all strains, 39 BbsI
for CNV strains 170, C33 and 39 BsaI for CNV HK) to enable
later ligation into the baculovirus transfer vector pTriex1.1.
Sequences were synthesized by BioBasic Inc. in the vector pUC57.
CNV-VP1 sequences were digested from pUC57 and re-ligated
into pTriex1.1 that had been digested with NcoI and NotI (NEB).
The correct sequence for all three CNV-VP1 inserts was
confirmed by sequencing.
Recombinant baculoviruses were generated using the flash BAC
baculovirus expression system as per the manufacturers instruc-
tions (Oxford Expression Technologies). Stock viruses were
Table 1. Overview of CNV strains used to design primer-probes and produce virus-like particles (VLP).
CNV strain Used in primer-probe design Used in VLP production (abbreviation) GenBank Accession Number
GIV.2/Bari/170/07-4/ITA Yes Yes (170) EU224456.1
GVI.1/Bari/91/2007/ITA Yes No FJ875027.1
FD210/2007/Ita Yes No JF939046
FD53/2007/Ita Yes No JF930689
C33/Viseu/2007/PRT Yes Yes (C33) GQ443611.1
Thessaloniki/30/2008/GRC Yes No GU354246.1
GVI.1/HKU_Ca035F/2007/HKG No Yes (HK) FJ692501.1
Six CNV sequences were used to design the primer-probe set used for qPCR detection. The strain GVI.1/HKU_Ca035F/2007/HKG had not been reported at time of
design. Three of the most diverse CNV sequences were selected for VLP production.
doi:10.1371/journal.pone.0081596.t001
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generated and titrated in Sf9 cells and stored in the dark at 4uC.
Protein expression was performed in Hi5 insect cells (Invitrogen).
Briefly, 16107 Hi5 insect cells were seeded into 106T150 flasks
then infected with recombinant baculovirus at a multiplicity of
infection of 5 pfu/cell. Infections were allowed to proceed for 6
days prior to protein harvest and VLP purification. VLP
purification was performed essential as described [18]. VLP was
released from infected Hi5 cells by freeze-thaw, followed by
clarification to remove cellular debris (60006g, 30 minutes) then
baculovirus removal (14,0006g for 30 mins). VLPs were partially
purified through a 30% w/v sucrose cushion in TNC buffer
(50 mM Tris HCl pH 7.4, 150 mM NaCl, 10 mM CaCl2)
containing the protease inhibitor leupeptin for 150,0006g for
2 hrs. The pelleted VLP was resuspended in TNC and further
purified by isopynic centrifugation in caesium chloride
(150,0006g, 18 hrs). The resultant VLP bands were collected by
puncture and the solution containing VLPs was dialysed against
PBS prior to quantification by BCA protein assay (Thermo
Scientific) and storage at 280uC.
ELISA Procedure
Ninety-six-well polystyrene microtiter plates (Nunc maxisorb,
Fisher Scientific) were coated overnight at 4uC with 75 ng of
pooled CNV VLPs consisting of 25 ng of each strain; 170, C33
and HK in 0.05 M carbonate/bicarbonate buffer (pH 9.6). Plates
were washed three times with 0.05% Tween 20 in phosphate
buffered saline (PBS-T) before blocking in 5% skimmed milk-PBS-
T for 1 h at 37uC and then three PBS-T washes. Plates were then
incubated for 3 h at 37uC with 1:50 dilution of each serum sample
in duplicate in 5% skimmed milk-PBS-T. Pooled human sera
(Sigma Aldrich), diluted 1:400, and 100 ng pooled GII human
norovirus VLPs were used as a positive control until a canine
positive control was identified. After three washes with PBS-T,
50 ml of horseradish peroxidase (HRP)-conjugated anti-dog IgG
antibody (Sigma Aldrich) diluted 1:5000 in 5% milk PBS–T, was
added to each well and incubated at 37uC for 1 h. The plates were
washed four times with PBS-T and bound antibody detected with
50 ml tetramethylbenidine (TMB, Sigma Aldrich) followed by
incubation at room temperature for 10 min. The reaction was
stopped with 1 N H2SO4 and the optical density (OD) was read at
450 nm (Spectromax M2 plate reader, Molecular Devices).
To eliminate the possibility that non-specific components of the
VLP preparation were identified by the canine sera, an
antigenically distinct vesivirus 2117 VLP was included in the
assay. The OD450 of a selection of serum samples incubated on
either carbonate/bicarbonate buffer coated wells or vesivirus 2117
coated wells was highly comparable. This confirmed that no non-
specific reactivity relating to the VLP preparation was occurring.
The background signal for each sample was hence determined by
measuring the OD450 of serum samples incubated with carbon-
ate/bicarbonate buffer alone. Background signal was then
subtracted from the OD450 of VLP coated wells to generate the
corrected OD450 value. A threshold value was established as the
mean of the OD450 of all buffer coated cells plus 3 standard
deviations. A serum sample was considered positive when the
corrected OD450 was higher than the threshold. Any serum
samples showing a positive response to pooled CNV VLPs were
subjected to further testing with individual CNV VLPs. Plates
were coated with 25 ng of individual VLPs in carbonate/
bicarbonate buffer and the protocol then repeated as above.
Evaluation of serological cross reactivity between different
norovirus strains was achieved using VLP competition assays.
Plates were coated with 25 ng/well of VLP overnight at 4uC.
CNV positive canine sera was incubated with a range of
concentrations of each of the either human norovirus VLPs, or
individual CNV VLPs (0.5, 1, 2 and 4 mg/ml) for 1 h at 37uC.
Vesivirus 2117 VLP was incubated with the canine sera as a
negative control. After the incubation period, 50 ml of each serum-
VLP combination was added to the previously VLP coated plates.
The remainder of the ELISA protocol was followed as detailed
above.
SDS-PAGE and Western Blot Analysis
VLPs were heated to approximately 100uC for 5 min in the
presence of SDS loading buffer and electrophoresed on 12.5%
SDS-polyacrylamide gels. For Coomassie blue staining, the gels
were incubated with Coomassie Blue for 1 h at room temperature
prior to de-staining. For western blotting, proteins were transferred
from SDS-polyacrylamide gels to polyvinylidene difluoride mem-
branes. The membranes were blocked for 1 h at room temper-
ature with 5% milk in PBS–Tween 20 (0.1%) and then incubated
overnight at 4uC with serum samples diluted 1:1000. The excess
antibody was washed three times in PBS–T and incubated for 1 h
with anti-canine IgG secondary antibody conjugated to horserad-
ish peroxidase (Sigma Aldrich). After washing away excess
secondary antibody, the bands were detected using enhanced
chemiluminescence reagent (GE Healthcare).
Table 2. Primers and probe sequences used in qPCR screen of canine stool samples for enteric viruses.
Virus Primer/Probe Ref
Canine norovirus F: GCTGGATGCGGTTCTCTGAC
R: TCATTAGACGCCATCTTCATTCAC
Probe: FAM-AGCGAGATTGCGATCTCCCTCCCACAT-BHQ
This report
Canine parvovirus F: AAACAGGAATTAACTATACTAATATATTTA
R: AAATTTGACCATTTGGATAAACT
Probe: VIC-TGGTCCTTTAACTGCATTAAATAATGTACC-BHQ
[32]
Canine enteric
coronavirus
F: TTGATCGTTTTTATAACGGTTCTACAA
R: AATGGGCCATAATAGCCACATAAT
Probe: Cy5-ACCTCAATTTAGCTGGTTCGTGTATGGCATT -BHQ
[32]
Equine arteritis virus
(internal control)
F: CATCTCTTGCTTTGCTCCTTAG
R: AGCCGCACCTTCACATTG
Probe: Cy5.5-CGCTGTCAGAACAACATTATTGCCCAC-BHQ2
[33]
Four primer-probe sets were used in the viral nucleic acid survey. CPV, CECoV and EAV primer-probe sets have previously been published whereas the CNV primer-
probe set was designed for this study.
doi:10.1371/journal.pone.0081596.t002
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Results
Samples Collected
Stool samples and clinical data were collected from 111 dogs
admitted to veterinary clinics distributed across the UK between
August 2012 and March 2013. The mean age of the dogs was 5.2
years (standard deviation 4.2 years), with 42 different breeds
represented. Diarrhoea and/or vomiting lasting more than 24 hrs
prior to admission, was reported in 52% of these cases. The
gastrointestinal clinical signs in a proportion of these cases were
unlikely to be attributable to primary gastroenteritis (e.g.
pyometra, foreign body ingestion), thus overall it was found that
43% of dogs enrolled in the study were suffering from
gastroenteritis, infectious or otherwise. Control samples were
collected from 117 healthy dogs (mean age 5.6 years, standard
deviation 3.6 years) from boarding kennels or belonging to
veterinary staff.
Viral RNA Survey
Nucleic acid extraction and qPCR were successfully performed
on 228 stool samples as determined by constant Ct values from the
internal extraction control RNA. In addition to CNV, samples
were systematically tested for the presence of canine parvovirus
(CPV) and canine enteric coronavirus (CECoV). Table 3 summa-
rises the results obtained. Enteric viruses, either CPV or CECoV,
were detected at high titre (.107 copies/ml stool) in 17.0% (8/47)
of dogs admitted with primary gastroenteritis. No viruses were
detected at significant titres in patients without gastroenteritis or in
the healthy control dogs. No samples were positive for CNV viral
RNA using the primer set described in Table 2. This indicates that
the overall prevalence of CNV in this population at the time of
sample collection was ,1.7% (Wilson binomial approximation,
confidence interval 95%).
Production and Purification of VLPs from VP1 of Three
CNV Strains
Recombinant baculoviruses expressing the VP1 proteins from
three distinct CNV isolates were generated and used in an insect
cell expression system to produce CNV VLPs. Following
purification by isopycnic centrifugation on a CsCl gradient, VLPs
were readily visualized and sedimented with a density of 1.32 g/
ml. Purified VLPs were quantified by spectrophotometry, and
examined by SDS-PAGE and staining with Coomassie blue
(figure 1). This showed a single major protein with apparent
molecular weight of 63 kDa for CNV strains 170 and C33, and
single major protein with apparent approximate molecular weight
of 57 kDa for strain HK. This difference in molecular weight was
expected based on VP1 sequence length. VLPs of an unrelated
calicivirus, vesivirus 2117, were included as a control.
Serological Survey
A total of 396 canine sera were tested by ELISA for antibodies
against CNV, 223 from a 1999–2001 cohort, and 173 from a
2012–2013 cohort. As part of an initial screen, CNV VLPs to
three strains (177, C33 and HK) were combined and a 1:50
dilution of canine sera examined for their reactivity to CNV.
Overall 189 were found to be seropositive to CNV. In the 1999–
2001 cohort, 85 dogs (38.1%) were seropositive and in the 2013/
2013 cohort, 104 (60.1%) dogs were seropositive. The increase in
seroprevalence between the two cohorts was statistically significant
(Z-test, p,0.001).
To determine the serological titres of seropositive dogs, ten
seropositive samples were randomly selected from both the 1999–
2001 cohort and the 2012–2013 cohort. Sera was serially diluted
two-fold from a starting dilution of 1:50, and added to pooled
CNV VLPs (25 ng each strain per well) coated onto 96-well plates.
A range of titres were identified (figure 2), varying from 1:1600 (1
dog) to 1:100. The most prevalent titre in this preliminary screen
was 1:400.
All 189 serum samples identified as positive by the initial ELISA
screen against pooled CNV VLPs, were then tested against
individual CNV VLPs. The results show significant variation
between the seroprevalence of different strains (figure 3). CNV
strain HK predominated in both cohorts of dogs, whereas strain
C33 showed the lowest seroprevalence in both groups. These data
also indicated that a proportion of dogs have seroconverted to
more than one of the CNV strains used in this study. In the 1999–
2001 cohort 30.6% dogs were seropositive to 2 or 3 strains, a
percentage that increased to 40.4% in the 2012–2013 cohort.
Table 3. Viruses detected in dogs with and without gastroenteritis.
Sample group (size) Canine norovirus Canine parvovirus Canine enteric coronavirus
Patients with gastroenteritis (47) 0 7 1
Patients without gastroenteritis (64) 0 0 0
Healthy controls (117) 0 0 0
qPCR was performed on nucleic acid extracted from stools of 228 dogs. Of these dogs, 47 were admitted to veterinary clinics with primary gastroenteritis, 64 dogs were
admitted to veterinary clinics with other clinical disease, and 117 dogs were healthy animals. Primer probes specific for canine norovirus (CNV), canine parvovirus (CPV)
and canine enteric coronavirus (CECoV) were used to assay for the enteric viruses.
doi:10.1371/journal.pone.0081596.t003
Figure 1. SDS-PAGE analysis of purified calicivirus VLPs. VLPs
from three CNV strains and an unrelated calicivirus, vesivirus 2117, were
analysed by SDS-PAGE. The molecular weights of VP1 of CNV isolates
C33 and 170 are larger than that of the third isolate HK. This is
attributed to the length of C33 and 170 VP1 sequences being 52 and 50
amino acids respectively longer than HK VP1.
doi:10.1371/journal.pone.0081596.g001
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Evaluation of CNV Antibody Cross Reactivity
To determine the strain specificity of the anti-CNV reactivity
identified in positive samples, a series of blocking assays were
performed on two selected samples. Firstly it was shown that pre-
incubating a serum sample positive to pooled CNV VLPs with
human norovirus VLPs from genogroup I and II, did not diminish
signal to CNV (figure 4A). This demonstrates that apparent
reactivity to CNV is not a consequence of cross-reactivity to
human norovirus strains. To investigate the antigenic relationship
between different CNV strains, blocking assays were next
performed using individual CNV strains. When a CNV seropos-
itive sample was pre-incubated with CNV strain 170 VLP,
subsequent detection in ELISA of strain 170 VLP coated on a
plate was reduced. Pre-incubation with VLPs of a different CNV
strain did not diminish signal. A similar result was shown when
serum was pre-incubated with CNV strain HK VLPs; detection of
HK VLPs by ELISA was reduced (figure 4B and 4C). No serum
that contained anti-CNV strain C33 antibodies was available in
sufficient quantities for the blocking assay, though the results from
pre-incubation with C33 VLPs were sufficient to indicate that
cross reactivity to strain 170 or HK was not occurring. This data
overall demonstrates that anti-CNV antibodies against the three
Figure 2. Serological titres to CNV. Ten dogs seropositive to CNV
from both the 1999–2001 and the 2012–2013 cohorts were randomly
selected to determine anti-CNV antibody titre. Corrected OD450 values
are plotted, calculated by subtracting the OD450 value of buffer-only
coated wells. The positive threshold was calculated from the mean plus
three times the standard deviation of the OD450 reading of buffer-only.
doi:10.1371/journal.pone.0081596.g002
Figure 3. Seropositive samples by ELISA to three different strains of CNV. Canine serum samples that were seropositive to pooled CNV
VLPs were screened against individual CNV VLP strains; 170, C33 and HK. (A) Venn diagrams represent seroprevalence of each CNV strain in the 1999–
2001 and the 2012–2013 cohorts. The number of dogs seropositive to one strain alone or combinations of strains are represented as percentages. (B)
The relative OD450 value to each CNV strains of each dog are represented by heatmaps. Each column represents a single dog. Positive threshold
value was established from the mean OD450 of coating buffer alone plus three standard deviations. Relative increase in OD450 values above the
positive threshold were calculated to enable fair comparison between experiments. A relative increase of ,1 indicates a seronegative sample,
represented by a white box. The degree of relative increase for samples is represented by increasing darkness of the corresponding box.
doi:10.1371/journal.pone.0081596.g003
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strains used in this study are strain specific, suggesting that CNV
exists as distinct serotypes.
Western blotting analysis of CNV VLPs using a representative
positive canine serum sample was used as an additional method to
confirm the specificity of anti-CNV antibodies (figure 5). By
ELISA, the selected serum was positive to CNV strains 170 and
HK, and this was proven to be the same by western blotting.
Serological Prevalence by Age
The age at the time of blood sampling was known for 93 out of
the 173 dogs in the 2012–2013 cohort. The mean age of dogs
seropositive to CNV was 8.1 years (SD 3.6), whereas the mean age
of seronegative dogs was 5.8 years (SD 3.8). The difference
between the age distribution of the two groups was statistically
significant (p=0.0076, Mann-Whitney test). Division of the dogs
into age-groups and calculation of the proportion of each group
seropositive to CNV showed that seroprevalence increases from
14% if less than 2 years of age, to almost 80% in the 6–8 year age
group (figure 6).
Discussion
In this study we describe the first evidence that CNV is present
in the UK dog population. Whilst previous reports have confirmed
the existence of CNV throughout Europe and the US [7,8,11,19],
we have now confirmed the presence of CNV-specific antibodies
in dogs in the UK, strongly suggesting CNV is circulating.
Seroprevalence to CNV in the canine serum samples collected
from 2012–2013 was 60.1%. This is comparable to the
seroprevalence to another enteric virus, CECoV, which has been
reported to vary between 54% and 78% in a population of UK
dogs [20][21]. CNV seroprevalence was unexpectedly high given
that CNV RNA was not detectable in 228 canine stool samples
analysed in this study. The high seroprevalence suggests that many
dogs are exposed to the virus, with the inability to detect actively
secreted viral RNA attributable to two possible factors. Firstly, it is
likely that, as with the majority of human norovirus infections in
man, CNV infection is very acute with virus only shed during a
short period of time. Acute gastroenteritis caused by human
norovirus in man results in peak viral shedding at 2–4 days after
infection. By 3 weeks after infection only 25% cases are still
positive for viral RNA [22]. Preliminary epidemiological data from
a study involving a kennel outbreak of CNV in seven dogs found
no virus detectable one week after the onset of clinical signs [9]. It
is worth noting that although human norovirus is responsible for
millions of infections worldwide each year, the virus is only
identified in approximately 12% of diarrhoeic samples submitted
Figure 4. Evaluation of cross-reactivity between antibodies
against human and canine noroviruses, and between different
CNV strains. Canine serum was pre-incubated with serial diutions of
either pooled human norovirus VLPs from genogroups I and II (GI/GII)
or pooled CNV VLPs. The ability to detect pooled CNV was analysed
using ELISA (A). Canine serum was then pre-incubated with serial
dilutions of each of the CNV strains VLPs separately. ELISAs were again
used to analyse the ability to detect CNV strain 170 (B) and strain HK (C).
No C33 seropositive sample of adequate titre was available for the
blocking assay.
doi:10.1371/journal.pone.0081596.g004
Figure 5. Western blotting of purified VLPs using seropositive
canine serum. Five different VLPs were separated by SDS-PAGE (2 mg
each). Gel A was stained with Coomassie blue to identify purified VLP
protein at the expected molecular weight. Gel B was used for western
blotting with a canine serum sample which was seropositive to CNV
strain 170 and HK by ELISA.
doi:10.1371/journal.pone.0081596.g005
Canine Norovirus in the UK Dog Population
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for analysis [23]. A second explanation for the low prevalence of
antigen detection could be due to the genetic heterogeneity of
CNV. Significant sequence variation has been shown between the
CNV strains characterized so far, and there is evidence of
recombination between canine norovirus strains and noroviruses
of different genogroups [13]. Design of the primer-probe used in
this study was based on a highly conserved region of the CNV
genome (NS7), but small sequence differences will affect the ability
of the viral sequence to be amplified. Although strains circulating
in the UK are antigenically similar to previously identified strains,
minor sequence differences could reduce the chance of detection
in a PCR screen. To address this, a primer set designed to be
broadly reactive to a wide range of noroviruses and sapoviruses
(p289/290 [24]) was used to reanalyze the samples. In addition, it
must be noted that the primer-probe used in the qPCR survey for
CNV RNA was designed prior to the publication of the HK
sequence. The HK sequence differences are such that the primer-
probe used in the qPCR survey would not detect strain HK. In
light of the results of the serosurvey, this issue was addressed
retrospectively to the first viral RNA survey. A new primer set was
designed to detect the most conserved region of the HK VP1
protein. A SYBR-based qPCR assay was used to screen all 228
stool samples for the presence of any norovirus strain using primer
pair p289/290 and also specifically for CNV strain HK using a
newly designed primer pair. No positive samples were identified
using either primer pair (data not shown).
Seroprevalence to the CNV strains surveyed in this study has
been shown to have significantly increased over the past decade in
the populations studied. In the 1999–2001 cohort of dogs 38.1%
were seropositive, whereas in the 2012–2013 cohort this propor-
tion has almost doubled. Not only does this data provide the first
proof that CNV has been present in dogs for at least 8 years prior
to its initial discovery [7], it also implies that the number of dogs
exposed to these strains of CNV has significantly increased during
this period. This conclusion does come with certain caveats
however, as the study populations of dogs used are not directly
comparable. The 1999–2001 samples were collected from dogs
that had been at a rehoming kennels for 3 weeks whereas the
2012–2013 dogs were all privately owned pets. Seroprevalence
and overall viral prevalence to many viruses is known to be higher
in facilities where dogs are kept in close contact [21][25]. This
does suggest that the apparent increase in seroprevalence to the
CNV strains studied is real, as typically owned pets will be exposed
less frequently to viruses than dogs in kennels. It would be valuable
to assess the current CNV seroprevalence in kenneled dogs, which
is predicted to be greater than 60%.
VLPs of three different CNV strains were pooled together to
establish the overall seroprevalence to the virus. CNV strains
included were identified in 2007 from Italy (170), Portugal (C33)
and Hong Kong (HK). Following the initial serosurvey with the
pooled VLPs, positive samples were entered into ELISAs with
VLPs from each of the individual strains separately. Our data
would indicate reactivity to all three strains in the UK dog
population. Blocking assays demonstrated no significant cross-
reactivity between the three CNV strains in the samples tested,
proving that antibodies generated in response to infection were
likely to be strain specific. The human immune response against
human norovirus is of short duration (up to 14 weeks) and is
homotypic, i.e. the immunity acquired for a genogroup or a
particular genotype does not provide effective protection against
another genogroup or genotype [26]. This study therefore reveals
that at least three antigenically distinct CNV strains have been
circulating in the UK dog population. This is similar to the co-
existence of human norovirus strains in the human population,
with both genogroup I and genogroup II strains circulating [27–
29].
Despite co-existence of multiple human norovirus strains,
genogroup II (GII) noroviruses are the most prevalent genogroup
worldwide with 96% of human outbreaks attributed to these
strains [28]. Our data also identified variation between the
prevalence of the different strains, with the highest seroprevalence
in both cohorts demonstrated for CNV strain HK (see table 1).
This strain has been classified as a GVI norovirus, along with the
Portuguese strain C33. However, strain HK has the highest
sequence identity (51.6%) to an intergenotype GII recombinant
human norovirus strain and it is suggested that strain HK may be
classified into a novel genogroup [19]. Aside from this phyloge-
netic information, it is not possible to determine if the higher
seroprevalence to strain HK in our study is due to a viral fitness
advantage, and further molecular characterization is required.
The age of seroconversion to CNV shows that exposure to the
virus typically occurs in the first few years of life. Seroprevalence
increases significantly in older dogs. This is comparable to the
seroconversion rates to human norovirus in man; seroprevalence
in children less than 2 years old is 20–30%, but this rapidly
Figure 6. Relationship of CNV antibody status to age. Age was
known for 93 dogs in the 2012–2013 cohort. (A) Box plot of age
distribution of dogs relative to seroconversion to CNV. The box
represents the interquartile range, with the band inside the box
representing the median age. The whiskers are the minimum and
maximum of all data. (B) Histogram representing the percentage of
dogs that have seroconverted to CNV in each age group. Numbers
inside bars indicate the quantity of samples associated with each data
point.
doi:10.1371/journal.pone.0081596.g006
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increases to 70–80% in older children [30,31]. It is speculated that
CNV isolation from stool samples using qPCR will be more likely
in a younger cohort of dogs.
To conclude, this report has not only demonstrated that CNV is
present within the UK dog population, but has also shown that
multiple strains of CNV are co-circulating. Evidence of exposure
to CNV prior to its first discovery in 2007 has also been presented,
and the rise in seroprevalence over time suggests this pathogen is
becoming increasingly common in the UK.
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